CD274 and cancer: Soon afterwards, anti-programmed death-ligand1 (PD-L1) mAbs including Atezolizumab (Tecentriq) (6), Avelumab (Bavencio) (7) and Durvalumab (Imfinzi) (8) were successively approved to be used in clinical cancer treatments.